Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

RORγt is the key transcription factor controlling the development and function of CD4(+) Th17 and CD8(+) Tc17 cells. Across a range of human tumors, about 15% of the CD4(+) T cell fraction in tumor-infiltrating lymphocytes are RORγ+ cells. To evaluate the role of RORγ in antitumor immunity, we have...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiao, Liu, Xikui, Moisan, Jacques, Wang, Yahong, Lesch, Charles A., Spooner, Chauncey, Morgan, Rodney W., Zawidzka, Elizabeth M., Mertz, David, Bousley, Dick, Majchrzak, Kinga, Kryczek, Ilona, Taylor, Clarke, Van Huis, Chad, Skalitzky, Don, Hurd, Alexander, Aicher, Thomas D., Toogood, Peter L., Glick, Gary D., Paulos, Chrystal M., Zou, Weiping, Carter, Laura L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215247/
https://www.ncbi.nlm.nih.gov/pubmed/28123897
http://dx.doi.org/10.1080/2162402X.2016.1254854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215247/
https://www.ncbi.nlm.nih.gov/pubmed/28123897
http://dx.doi.org/10.1080/2162402X.2016.1254854

Ejemplares similares